1. Introduction {#sec1}
===============

Nasopharyngeal carcinoma (NPC) presents regional differences in incidence, such as high incidences in North Africa and Southern China \[[@B1]\]. More than 60% of NPC patients at diagnosis are in late stages or even present with metastasis although many biomarkers were reported to be useful for early detection such as Epstein-Barr virus (EBV) antibodies \[[@B2]\]. Therefore, there is still an urgent need to identify the biomarkers for cancer diagnosis and therapeutic guidance.

Gene fusions derived generally from chromosomal rearrangements are considered as cancer-related genetic events, and their products including RNAs and proteins are identified as specific diagnostic and therapeutic targets for cancers such as hematologic malignancy and lung adenocarcinoma \[[@B3], [@B4]\]. However, certain chimeric transcripts can be formed without chromosomal rearrangements. Previous studies demonstrated that a fusion transcript named*SLC45A3-ELK4* was formed with exon 1 of*SLC45A3* and the last 4 exons of*ELK4*\[[@B5], [@B6]\], which acted as oncogenes in prostate tumor cells without chromosomal changes \[[@B7]\]. Additionally, many studies showed a plenty of fusion transcripts present in normal and/or tumor cells \[[@B8]--[@B12]\]. Therefore, fusion genes might be occurred in normal or tumors cells with/without chromosomal changes. Although previous studies have already reported some tumor specific fusion genes in NPC, all of them occur accompanied with the rearrangement of chromosomes \[[@B13], [@B14]\].

Herein, we carried out RNA sequencing and discovered a novel type of fusion gene, trans-splicing chimeric transcript*SEPT7P2-PSPH*. In addition, we performed*in vitro* studies to demonstrate that the ability of cell invasion, migration, proliferation, colony formation, and transforming were activated when the expression of the transcript was decreased, indicating that*SEPT7P2-PSPH* act as the tumor suppressor gene role in NPC tumorigenesis.

2. Materials and Methods {#sec2}
========================

2.1. Primary Tumors and Pair-End RNA Sequencing {#sec2.1}
-----------------------------------------------

Ten formalin fixed paraffin embedded (FFPE) NPC samples were retrieved from the Department of Pathology of Sun Yat-sen University Cancer Center (SYSUCC, Guangzhou, China). All tumor samples were reviewed by two experienced pathologists. Total RNA were extracted from ten FFPE tissues with RNeasy FFPE Kit (QIANGEN, Hilden, Germany) according to the manufacturer\'s instructions for RNA sequencing. cDNA libraries were prepared according to the standard protocol provided by the mRNA-seq sample Pre Kit (Illumina Inc, California, USA) and sequenced (90 nt paired-end) on the Illumina Hi-seq 2000. To identify fusion genes from paired-end RNA sequencing, the data were analyzed by the computational pipeline called SOAPfusion, which uses clusters of discordant paired-end alignments to inform a split-read alignment analysis for finding fusion boundaries \[[@B15]\]. The UCSC*H. sapiens* reference genome (build hg19) was used for alignments. The written informed consent was obtained from each patient and this study was approved by Ethics Committee and Institutional Review Board of SYSUCC.

2.2. Cell Cultures, Reverse Transcription and Sanger Sequencing {#sec2.2}
---------------------------------------------------------------

CNE1 and 6-10B used in the study were cultivated in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Gibco, California, USA) in a humidified 5% CO~2~ incubator at 37°C. All cultivations involved have been sustained within 6 months. Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions. Reverse transcription was subsequently performed with PrimeScript RT reagent Kit with gDNA Eraser (TaKaRa, Kusatsu, Shlga, Japan). The products were employed with specific primers for Sanger sequencing to confirm potential fusion transcripts. The primers were shown as follows:  *SEPT7P2-PSPH* 1-sense: 5′-TTACGACTTCTCGGTCTTCGG-3′  *SEPT7P2-PSPH* 1-anti-sense: 5′-CGTCCTCAACGCCACAGATT-3′

2.3. Quantitative RT-PCR {#sec2.3}
------------------------

Quantitative RT-PCR was performed using the ABI 7500 Real-time PCR system (Applied Biosystems, California, U.S.A) and SYBR Premix EX Taq (TaKaRa, Kusatsu, Shlga, Japan). All reactions were carried out in triplicate. The housekeeping gene*GAPDH* was used as normalization control. The relative expression levels of target gene*SEPT7P2-PSPH* were calculated by 2^−△△*Ct*^ method, in which △*Ct* = mean*Ct SEPT7P2-PSPH*-- mean*Ct* control, where*Ct* values are the cycle threshold for each sample \[[@B16]\]. Specific primers were shown as follows:  *SEPT7P2-PSPH* 2-sense: 5′-ACCTGAGCCTGGGAGGAAA-3′  *SEPT7P2-PSPH* 2-anti-sense: 5′-GTCAACATCAAAACACACAGCATC-3′

2.4. Immunohistochemistry (IHC) Staining {#sec2.4}
----------------------------------------

4 *μ*m thick FFPE NPC slides were used to perform IHC staining. Firstly, the tumor slides were deparaffinized. Antigen retrieval procedure was then performed in a pressure cooker in 1 mM sodium citrate (Sangon Biotech, Shanghai, China) for 1.5 minutes.*PSPH* rabbit polyclonal (Proteintech, Wuhan, China) was diluted with SigalStain antibody diluent (Cell Signaling Technology, Danvers, MA, USA) at 1:400 for 1 h. Universal secondary antibody (Gene Tech, Shanghai, China) was applied for 15 minutes. Subsequently, diaminobenzidine was used as chromogens and slides were counterstained with haematoxylin before mounting.*PSPH* IHC was scored according to the scoring criteria including intensity and percentage as follows: 0, no staining; 1+, faint cytoplasmic reactivity without any background staining; 2+, moderate cytoplasmic reactivity; and 3+, granular cytoplasmic reactivity of strong intensity; 0, 0-25%; 1, 25%-50%; 2, 50%-75% \[[@B17]\].

2.5. siRNA Transfection {#sec2.5}
-----------------------

Small interfering RNAs which targeted the fusion gene (si-SP1 5′-GUUGUUTTTTCCTCCCUGG-3′; si-SP2 5′-UUGUUTTTTCCTCCCUGGC-3′) were bought from RIBOBIO Company (Guangzhou, China). CNE1 and 6-10B cells were transfected with oligonucleotides (20 nmol/L) using the Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions.

2.6. Western Blotting {#sec2.6}
---------------------

Cell lysis was carried out in RIPA buffer including protease inhibitor and phosphatase inhibitor cocktails (Biostool, Shanghai, China). The protein extracts were isolated from the same amounts using 12% SDS-PAGE gels. After that all the abstracts were transferred to polyvinylidene fluoride membranes (Merck Millipore, Billerica, MA, USA). Subsequently, the membranes were incubated with rabbit polyclonal anti-*PSPH* antibody 1:1000 (Proteintech, Wuhan, China). And then, the incubation was performed with goat anti-rabbit IgG antibody 1:5000 (Abcam, Cambridge, UK). Anti-*β*-actin antibody (Affinity, Ancaster, Canada) was acted as a protein control.

2.7. Cell Proliferation Assay {#sec2.7}
-----------------------------

Cell proliferation was evaluated by conducting CCK-8 assays. 1000 cells were seeded per well in 96-well plates in triplicate. After incubation with 10uL of CCK8 agent (Dojindo, Kumamoto, Japan) for 3 hours in the dark in an incubator at 37°C, the absorbance value was measured at 450 nm every 12 hours.

2.8. Boyden Chamber Assays {#sec2.8}
--------------------------

Invasion and migration abilities were examined after the siRNA of*SEPT7P2-PSPH* transfection. Boyden chambers (Corning, New York, USA) with 8 *μ*m inserts equipped with (invasion) or without (migration) Matrigel were placed in the 24-well plate. A total of 5 × 10^4^ cells were suspended in 200 *μ*L RPMI 1640 without serum in the upper chambers and cultured at 37°C for 24 hours. The cells which went through the inserts were stained with 0.5% crystal (Sangon, Shanghai, China). Then, the number of cells per field of view was counted under phase-contrast microscopy.

2.9. Colony Formation Assay {#sec2.9}
---------------------------

500 transfected cells were plated in six-well plates and cultured for 7 or 12 days. All the colonies were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet (Sangon, Shanghai, China) for quantification. All the experiments were performed in triplicate.

2.10. Anchorage-Independent Assay {#sec2.10}
---------------------------------

In the 6-well plate, the bottom layers were the mixture of equivalent volumes of 1.2% agarose (Sangon, Shanghai, China) in PBS and medium containing 20% FBS. 5000 cells were suspended in the upper layer containing 1 ml 0.4% soft agarose.

2.11. Statistical Analysis {#sec2.11}
--------------------------

All statistical analyses were performed using SPSS 16.0 software (IBM, Armonk, NY, USA) and GraphPad Prism version 5.0 (GraphPad Software). The data are presented as the mean ± SEM from at least three independent experiments. Two-tailed Student\'s*t*-tests were conducted to compare the difference between groups. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method, and the survival curves were compared with the log-rank test method. All tests were two-sided, and P \< 0.05 was considered as statistically significant.

3. Results {#sec3}
==========

3.1. Novel Fusion Genes Discovered in NPC {#sec3.1}
-----------------------------------------

We found 60 transcripts of fusion genes using RNA sequencing including 28 inter- and 32 intrachromosomal fusions from ten FFPE NPC tissues ([Table 1](#tab1){ref-type="table"}). Paired-end reads featured by two uncorrelated genes or spanned exon-exon junctions were nominated as putative chimeric genes (Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}). Fusion genes recurrently occurred in more than one sample were selected for subsequent investigation. A novel fusion gene named*SEPT7P2-PSPH* was discovered in 5 out of 10 samples and located on chromosome 7 ([Figure 1(b)](#fig1){ref-type="fig"}). To validate this newly found transcript, we designed specific primers matching the region that contained the fusion point at the mRNA level. The mRNA level of this fusion gene was validated using Sanger sequencing in the 5 samples previously and consistent with that identified by RNA sequencing ([Figure 1(c)](#fig1){ref-type="fig"}).

The transcript was formed with the exon 1 of*SEPT7P2* and the exon 4 of*PSPH*. The practical distance between the two exons are 10.2 Mb on chromosome 7. To estimate if there existed a genomic DNA rearrangement with the chimeric RNA, we designed 30 primer pairs to amplify the entire genome sequences between exon 1 and exon 2 of*SEPT7P2* as well as the genome sequences between exon 3 and exon 4 of*PSPH*(Supplementary [Table 1](#supplementary-material-1){ref-type="supplementary-material"} and [Figure 1(d)](#fig1){ref-type="fig"}). However, all the segments were amplified by PCR indirectly indicating the fact that chromosomal arrangement was absent ([Figure 1(e)](#fig1){ref-type="fig"}).

3.2. The Expression of the Fusion Genes in Cell Lines and Tissues {#sec3.2}
-----------------------------------------------------------------

In addition, we have investigated several tumor cell lines including Hela, Hep3B, NP69, CNE1, 6-10B, SUNE2, CNE2, HONE1, and 5-8F. All the cell lines were confirmed to harbor the fusion gene ([Figure 2(a)](#fig2){ref-type="fig"}). Interestingly, we found that the relative expression of*SEPT7P2-PSPH* was higher in the cohort of nasopharyngitis than that in NPC patients ([Figure 2(b)](#fig2){ref-type="fig"}, P \< 0.05). Collectively, these results indicated that the newly found transcript was not peculiar to tumor cells. Analogous studies have been published to demonstrate the noncanonical chimeric transcript \[[@B10]--[@B12]\]. Simultaneously, we performed western blotting assay to discover if there would be a new type of fusion protein accompanied by the transcript. Anti-*PSPH* polyclonal antibody was applied in the nine tumor cell lines. It was shown that the putative fusion protein did not exist and only the protein of full-length*PSPH* was confirmed by western blot with the band at 25 kDa ([Figure 2(c)](#fig2){ref-type="fig"}).

3.3. Knocking Down*SEPT7P2--PSPH* Upregulated the Level of*PSPH* Protein and Promoted Cell Proliferation and Migration {#sec3.3}
----------------------------------------------------------------------------------------------------------------------

We carried out*in vitro* experiments to confirm the potential biologic function of the*SEPT7P2-PSPH* transcript. NPC cell lines CNE1 and 6-10B were selected to explore the effect of*SEPT7P2-PSPH* on NPC tumorigenesis. When compared with the negative control group, the expression of the chimeric transcript substantially decreased after two specifically designed siRNAs, siSP1 and siSP2, were transiently transfected into the cell lines. Also, there was no novel fusion protein synthesized. After transfection for 48 hours, the expression of*SEPT7P2-PSPH* at mRNA level was decreased sharply whereas the expression of*PSPH* protein was upregulated in both cell lines (Figures [2(d)](#fig2){ref-type="fig"}-[2(e)](#fig2){ref-type="fig"} and Supplementary [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}). This may indirectly show the phenomenon that the chimeric RNA fusion did not produce a new fusion protein.

However, the expression level of down-stream gene\'s protein was reversely influenced by the occurrence of the fusion between*SEPT7P2*and*PSPH*. We subsequently performed cell proliferation assays to explore the effects of the fusion gene on the growth of CNE-1 and 6-10B. The cells transfected with si-*SEPT7P2--PSPH-*1 (siSP1) and si-*SEPT7P2--PSPH-*2 (siSP1) grew faster than those with negative control ([Figure 3(a)](#fig3){ref-type="fig"}, P \< 0.05). Low expression of*SEPT7P2-PSPH* may contribute to tumor cell proliferation. For investigating its influence on the transforming ability of NPC cells, we conducted both colony formation assay and anchorage-independent growth assay. Strikingly, CNE1 and 6-10B cells with siSP1 and siSP2 formed larger colonies than the negative control groups, which was reversely correlated with the expression of the chimeric RNA (Figures [3(b)](#fig3){ref-type="fig"} and [3(c)](#fig3){ref-type="fig"}, P \< 0.05). To evaluate its biological function with migration and invasion, Boyden chamber assays*in vitro* have been conducted. As shown in [Figure 3(d)](#fig3){ref-type="fig"}, knocking down*SEPT7P2-PSPH* with siSP1 and siSP2 markedly enhanced the migration and invasion of NPC cells (P \< 0.05).

3.4. *PSPH* Expression and Prognosis of NPC Patients {#sec3.4}
----------------------------------------------------

To investigate the expression status of*PSPH* in NPC, we performed IHC experiment for*PSPH* in 72 FFPE NPC specimens ([Figure 4](#fig4){ref-type="fig"}). The result revealed that the patients with high PSPH expression showed a tendency with shorter PFS and OS in NPC patients though there was no statistically significant (Figures [5(a)](#fig5){ref-type="fig"} and [5(b)](#fig5){ref-type="fig"}, P = 0.205, P = 0.106).

4. Discussion {#sec4}
=============

The present study is the first to identify trans-splicing chimeric transcript*SEPT7P2-PSPH* without chromosomal rearrangement in NPC patients. Knocking down of this transcript may promote cell proliferation and metastasis/invasion possibly due to the upregulation expression of the downstream gene*PSPH*.

Traditionally, chromosome rearrangements can generate fusion genes which are in an intimate relationship with tumor carcinogenesis. To date it makes possible to discover more and more valuable fusion genes acting as a crucial regulator in cancer formation, maintenance, and evolution. Previous studies have shown that chimeric RNAs in normal and cancer cells can be generated by intergenic splicing in the absence of chromosome rearrangements \[[@B7]--[@B9], [@B18], [@B19]\]. This kind of fusion gene can be used as "noncanonical chimeras". It has been reported that there are two methods for "noncanonical chimeras" formation involving cis-splicing and trans-splicing of adjacent genes \[[@B10]\]. Cis-splicing fusions tend to occur between two genes that are located within 30kb in the same chromosome. Trans-splicing can be classified into two types: intragenic trans-splicing taking place between two pre-mRNAs transcribed from the same genome loci and intergenic trans-splicing that is from two different genome loci.*SEPT7P2-PSPH* can be classified as intergenic trans-splicing located on chromosome 7 aligned with the fact that the up- and downstream genes are 10.2Mb distance.

Furthermore, we found that metastasis/invasion and proliferation of the tumor cells were inversely enhanced after the transcript had been knocked down. This was different from previously analogous studies \[[@B14], [@B20]\]. The western blot result showed that there was no newly synthetic fusion protein accompanied with the chimeric RNA. Only the*PSPH* protein was translated from the downstream gene*PSPH* and was overexpressed after the chimeric RNA had been knocked down. The sequence of the chimeric RNA indicated that both of the two genes\' start codons were retained after the occurrence of the fusion, one in exon 1 of*SEPT7P2* and another in exon 4 of*PSPH*. It seemed that the start codon in exon 1 of*SEPT7P2* depressed the transcription of*PSPH*. The reason why fusion genes have the ability of oncogenesis can be illuminated that the new synthesized fusion products possess the tumorigenic function. Another reason is that the preoncogene could be upregulated after connected to a stronger promoter or the antioncogene could be downregulated after fused with a weaker promoter \[[@B21]\].

*SEPT7P2* is a pseudogene which has been proved to be related to SEPT7 and expressed in all tissue types \[[@B22]\], playing a role in multiple biological processes including vesicle trafficking, apoptosis, remodeling of the cytoskeleton, neurodegeneration, and neoplasia.

Some researchers have reported that abnormal expression of*PSPH* is strongly relevant to the hepatocellular carcinoma patients\' mortality as well as the critical importance on*cMyc*-induced cancer progression both*in vitro*and*in vivo*\[[@B23]\]. The level of*PSPH* has the relationship with breast cancer and lacrimal gland adenoid cystic carcinoma \[[@B24], [@B25]\]. In our study, high expression of*PSPH* was the tendency to NPC patients\' poor survival though there was no statistically significant. Two previous studies indicated that*PSPH* was abundantly expressed in proliferating embryonic and hematopoietic stem cells and neural progenitors of the developing brain \[[@B26], [@B27]\]. Furthermore, inhibition of*PSPH* induced programmed cell death in tonsillar cell cultures \[[@B28]\]. In another words,*PSPH* plays an important oncogenic role in regulating the ability of cell proliferation and apoptosis. Hence, we put forward the hypothesis that it could be the*PSPH* overexpression induced when the pseudogene*SEPT7P2* and*PSPH* fuse with each other. Recently, some studies demonstrated that trans-splicing can become one of the tumor-targeting methods in cancer related treatment, in which trans-splicing ribozyme may function as a potential anticancer agent via stimulating anticancer gene activity \[[@B29]\]. However, such role of the transcript*SEPT7P2*-*PSPH* in NPC warrants the further study.

5. Conclusions {#sec5}
==============

The trans-splicing chimeric transcript*SEPT7P2*-*PSPH* in our study might be a tumor suppressor gene in NPC tumorigenesis, potentially having the role of anticancer activity.
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Supplementary Figure 1. The*PSPH* expression was verified by western blotting after interfering expression of*SEPT7P2-PSPH* by the two specific siRNA. Supplementary Table 1. Primer sequences.

###### 

Click here for additional data file.

![*RNA sequencing was used to discover SEPT7P2-PSPH fusion gene in NPC.* (a) Detection of*SEPT7P2-PSPH* fusion gene*via* RNA sequencing. The reads are aligned across the junction of the predicted fusion transcripts. (b) Circos plot of*SEPT7P2-PSPH* fusion gene revealed the fusion existing in chromosome 7. (c) The fusion breakpoint was verified using Sanger sequencing. (d) A schematic illustration of the amplified regions of fusion gene with exons 1-2 of*SEPT7P2* and exons 3-4 of*PSPH*. (e) The sequences between exons 1 and 2 of*SEPT7P2* and the sequences between exons 3 and 4 of*PSPH* were all amplified by RT--PCR.](JO2019-1654724.001){#fig1}

![*SEPT7P2-PSPH expression*. (a) By RT--PCR, the*SEPT7P2-PSPH* fusion transcripts were verified in nine cell lines. (b) The relative expression of*SEPT7P2-PSPH* was higher in nasopharyngitis compared with those in NPC patients using quantitative RT-PCR (P \< 0.05). (c) Full-length*PSPH* protein was expressed in nine cell lines by western blotting and no relevant chimeric fusion protein was detected. Expression of*SEPT7P2-PSPH* was knocked down by the specific siRNA. The suppression effect was verified by quantitative RT-PCR and western blotting, respectively (d, e, n = 3; two-tailed Student\'s t-tests, ^*∗∗*^*P* \< 0.01 and ^*∗∗∗*^*P* \< 0.001).](JO2019-1654724.002){#fig2}

![*Knocking down SEPT7P2-PSPH can promote cell proliferation and colony formation of NPC cells.* (a) CCK8 assays showed that cell proliferation was significantly enhanced after the specific siRNA interfered with the expression of*SEPT7P2-PSPH* (n = 3; two-tailed Student\'s t-tests, ^*∗*^*P* \< 0.05, ^*∗∗*^*P* \< 0.01 and ^*∗∗∗*^*P* \< 0.001). (b) and (c) Knocking down*SEPT7P2-PSPH*by siRNA can promote the colony-formation ability of CNE1 and 6-10B cells (n = 3; two-tailed Student\'s t-tests, ^*∗∗*^*P* \< 0.01 and ^*∗∗∗*^*P* \< 0.001). (d) Cell migration and invasion assays revealed that the abilities of migration and invasion were enhanced after interfering with specific siRNA.](JO2019-1654724.003){#fig3}

![Representative IHC staining with negative (a), low (b), moderate (c), high, and (d)*PSPH* expression. Scale bar, left panel 500 *μ*m; right panel 100 *μ*m.](JO2019-1654724.004){#fig4}

![*Survival analysis.* (a) and (b) Kaplan-Meier analysis of progression-free survival and overall survival for NPC patients with low (n=27) versus high (n=45) expression of*PSPH* through immunohistochemistry (IHC) staining.*P* value was determined by the log-rank test (P \> 0.05).](JO2019-1654724.005){#fig5}

###### 

60 transcripts of fusion genes discovered by NGS including 28 inter- and 32 intrachromosomal fusions from ten FFPE NPC tissues.

  up_gene    up_chr   down_gene   down_chr   Fusion_Type
  ---------- -------- ----------- ---------- -----------------------
  IGKC       chr2     CALR        chr19      INTERCHR-DS
  IGKJ5      chr2     CALR        chr19      INTERCHR-DS
  MALAT1     chr11    RFWD2       chr1       INTERCHR-DS
  MRPS18A    chr6     C5orf25     chr5       INTERCHR-DS
  RN7SL1     chr14    IGKC        chr2       INTERCHR-DS
  RN7SL1     chr14    IGKJ5       chr2       INTERCHR-DS
  RNU6-1     chr15    SNORD3A     chr17      INTERCHR-DS
  RNU6-33    chr4     SNORD3A     chr17      INTERCHR-DS
  RNU6-42    chr3     RPS3        chr11      INTERCHR-DS
  RNU6-42    chr3     SNORD15A    chr11      INTERCHR-DS
  RNU6-42    chr3     SNORD3A     chr17      INTERCHR-DS
  SAMD12     chr8     ATP10D      chr4       INTERCHR-DS
  ATP1B2     chr17    HSD17B12    chr11      INTERCHR-SS
  E2F4       chr16    RPL14       chr3       INTERCHR-SS
  EFCAB4A    chr11    RN7SK       chr6       INTERCHR-SS
  IGHG1      chr14    NINJ1       chr9       INTERCHR-SS
  IGKC       chr2     CSNK2A2     chr16      INTERCHR-SS
  IGKJ5      chr2     CSNK2A2     chr16      INTERCHR-SS
  MIDN       chr19    ALMS1       chr2       INTERCHR-SS
  PDE4B      chr1     PPP6R3      chr11      INTERCHR-SS
  POU2AF1    chr11    PARP11      chr12      INTERCHR-SS
  RNU6-2     chr10    SNORD3A     chr17      INTERCHR-SS
  RNU6-36    chr12    SNORD3A     chr17      INTERCHR-SS
  RNU6-42    chr3     SNHG12      chr1       INTERCHR-SS
  RPL14      chr3     GLS         chr2       INTERCHR-SS
  SLC7A5P2   chr16    PHC3        chr3       INTERCHR-SS
  SMARCA2    chr9     RPL14       chr3       INTERCHR-SS
  ZNF827     chr4     ZNF318      chr6       INTERCHR-SS
  ADCK4      chr19    NUMBL       chr19      INTRACHR-SS-OGO-0GAP
  AP5S1      chr20    MAVS        chr20      INTRACHR-SS-OGO-0GAP
  C12orf74   chr12    PLEKHG7     chr12      INTRACHR-SS-OGO-0GAP
  COL7A1     chr3     UCN2        chr3       INTRACHR-SS-OGO-0GAP
  CTBS       chr1     GNG5        chr1       INTRACHR-SS-OGO-0GAP
  CTSD       chr11    IFITM10     chr11      INTRACHR-SS-OGO-0GAP
  EEF1D      chr8     NAPRT1      chr8       INTRACHR-SS-OGO-0GAP
  JAK3       chr19    INSL3       chr19      INTRACHR-SS-OGO-0GAP
  KIAA0101   chr15    CSNK1G1     chr15      INTRACHR-SS-OGO-0GAP
  LSM10      chr1     STK40       chr1       INTRACHR-SS-OGO-0GAP
  MAPK7      chr17    RNF112      chr17      INTRACHR-SS-OGO-0GAP
  MRPS31P2   chr13    TPTE2       chr13      INTRACHR-SS-OGO-0GAP
  NPL        chr1     DHX9        chr1       INTRACHR-SS-OGO-0GAP
  PIK3R2     chr19    IFI30       chr19      INTRACHR-SS-OGO-0GAP
  POLA2      chr11    CDC42EP2    chr11      INTRACHR-SS-OGO-0GAP
  PPCS       chr1     CCDC30      chr1       INTRACHR-SS-OGO-0GAP
  PROM2      chr2     KCNIP3      chr2       INTRACHR-SS-OGO-0GAP
  PSTPIP2    chr18    EPG5        chr18      INTRACHR-SS-OGO-0GAP
  RRM2       chr2     C2orf48     chr2       INTRACHR-SS-OGO-0GAP
  STYXL1     chr7     TMEM120A    chr7       INTRACHR-SS-OGO-0GAP
  TTTY15     chrY     USP9Y       chrY       INTRACHR-SS-OGO-0GAP
  VMAC       chr19    CAPS        chr19      INTRACHR-SS-OGO-0GAP
  WDFY1      chr2     AP1S3       chr2       INTRACHR-SS-OGO-0GAP
  WNT10B     chr12    ARF3        chr12      INTRACHR-SS-OGO-0GAP
  EEF1DP3    chr13    FRY         chr13      INTRACHR-SS-OGO-1GAP
  HACL1      chr3     COLQ        chr3       INTRACHR-SS-OGO-1GAP
  IRF6       chr1     C1orf74     chr1       INTRACHR-SS-OGO-1GAP
  TMSB4Y     chrY     KALP        chrY       INTRACHR-SS-OGO-1GAP
  RMPP       chr9     SMU1        chr9       INTRACHR-SS-OGO-53GAP
  FGFR3      chr4     TACC3       chr4       INTRACHR-SS-RGO
  SEPT7P2    chr7     PSPH        chr7       INTRACHR-SS-RGO
  SRGAP2B    chr1     SRGAP2C     chr1       INTRACHR-SS-RGO

chr, chromosome.
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